Navigation Links
Ascenta Therapeutics Announces Presentation of Promising Results From Clinical Trials of AT-101 in Prostate, Brain, and Lung Cancers at 2009 ASCO Annual Meeting
Date:6/1/2009

so presented(3) . Fifty-six patients were enrolled with daily oral doses of AT-101 given for 21 of 28 days in repeated cycles. The treatment was well tolerated, with a low incidence of serious adverse events and no unique central nervous system toxicities. Responses were evaluated in 43 patients and included one confirmed partial response and 8 patients with stable disease, representing half of the patients still alive at the time of analysis. Progression-free survival (PFS) in these patients ranged from 8 to 13 months. Determination of the impact of AT-101 on overall survival (OS), the primary endpoint, is ongoing.

AT-101 in Lung Cancer

Reports from two studies in lung cancer also showed promising signals of antitumor effect. The first presentation described results from a randomized, double-blind, placebo-controlled Phase II trial in 105 patients who had received one prior chemotherapy regimen for non-small cell lung cancer (NSCLC)(4). While the primary endpoint, a statistically significant improvement in PFS, was not met, the docetaxel plus AT-101 arm demonstrated a positive trend in OS, as reflected in the Kaplan-Meier curves (hazard ratio 0.82). This group also demonstrated a 33 percent increase in median survival and a 34 percent increase in 6-month survival compared to the docetaxel plus placebo arm. Common adverse events included fatigue (18 percent), anemia (18 percent) and dyspnea (18 percent). Using NSCLC cell lines, a genomic profile predicting response to AT-101 was developed in collaboration with Duke University. Opportunities to validate this biomarker will be pursued in future trials.

The second presentation reported on an open-label, Phase I/II study of AT-101 in combination with topotecan in patients with relapsed or refractory small cell lung cancer (SCLC) who had received prior platinum-based first line chemotherapy(5). The Phase II portion of the trial included 25 patients div
'/>"/>

SOURCE Ascenta Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Ascenta Therapeutics Announces Results of Preclinical Evaluation of AT-406 in Multiple Cancer Models
2. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
3. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
4. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
5. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
6. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
7. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
8. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
9. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
10. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
11. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... TORONTO, May 5, 2015 /PRNewswire/ - Aptose Biosciences Inc. (NASDAQ: ... financial results for the three months ended March 31, ... all amounts are in Canadian dollars. ... year end from May 31 to December 31. As ... being reported is for the three months ended March ...
(Date:5/5/2015)... 5, 2015  23andMe, Inc., the leading personal genetics ... Research Study in collaboration with Pfizer Inc. The ... erythematosus, more commonly known as lupus, into the study ... effort is also in collaboration with the Lupus Research ... May. Approximately 1.5 million people in the ...
(Date:5/5/2015)... Mich. (PRWEB) May 05, 2015 ... publishing services to develop custom course materials for smaller ... annual enrollments as low as 200 students. , ... a broader range of higher education instructors,” said Jeff ... the country, we can do our part to make ...
(Date:5/5/2015)... -- Psyche Systems Corporation and Luminate Health have recently ... that helps labs comply with new federal HHS legislation ... patients engage with these results, and improves provider workflow. ... HIPAA-compliant digital platform that gives labs an easy way ... results, and uniquely connects labs, physicians, and patients with ...
Breaking Biology Technology:Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 2Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 3Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 4Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 5Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 6Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 7Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 823andMe Launches the Lupus Research Study in Collaboration with Pfizer Inc. 223andMe Launches the Lupus Research Study in Collaboration with Pfizer Inc. 3Hayden-McNeil Expands Publishing Program to Service Lower Enrollment Courses 2Psyche Systems Corporation Forms Strategic Alliance with Luminate Health to Provide First-of-its-kind Patient Access Solution 2Psyche Systems Corporation Forms Strategic Alliance with Luminate Health to Provide First-of-its-kind Patient Access Solution 3
... Quarter and Year End 2009 Financial Results , VANCOUVER , ... will host a conference call discussing its financial results for the fourth ... March 4, 2010 at 9:00 AM ET ( 6:00 ... March 4, 2010 is as follows: , North America ...
... RICHMOND, Calif. , Feb. 3 Sangamo BioSciences, Inc. (Nasdaq: ... and accomplishments and provided an outlook for 2010. , For the fourth ... of $2.4 million , or $0.05 per share, compared to ... share, for the same period in 2008. As of December 31, 2009 ...
... , ... Label Printer powers low cost label and barcode printing for RURO lab management software. ... (PRWEB) February ... announced support for the newly available Brady BBP™11 Label Printer, a compact, budget friendly ...
Cached Biology Technology:Angiotech Pharmaceuticals Announces Conference Call and Webcast 2Sangamo BioSciences Reports Fourth Quarter and Full Year 2009 Financial Results 2Sangamo BioSciences Reports Fourth Quarter and Full Year 2009 Financial Results 3Sangamo BioSciences Reports Fourth Quarter and Full Year 2009 Financial Results 4Sangamo BioSciences Reports Fourth Quarter and Full Year 2009 Financial Results 5Sangamo BioSciences Reports Fourth Quarter and Full Year 2009 Financial Results 6Sangamo BioSciences Reports Fourth Quarter and Full Year 2009 Financial Results 7Sangamo BioSciences Reports Fourth Quarter and Full Year 2009 Financial Results 8Sangamo BioSciences Reports Fourth Quarter and Full Year 2009 Financial Results 9Sangamo BioSciences Reports Fourth Quarter and Full Year 2009 Financial Results 10Sangamo BioSciences Reports Fourth Quarter and Full Year 2009 Financial Results 11Sangamo BioSciences Reports Fourth Quarter and Full Year 2009 Financial Results 12Sangamo BioSciences Reports Fourth Quarter and Full Year 2009 Financial Results 13RURO and Brady Team to Deliver Solutions for Mid-market Laboratory Applications 2RURO and Brady Team to Deliver Solutions for Mid-market Laboratory Applications 3
(Date:5/5/2015)... , May 5, 2015, NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market, reminds investors ... Chief Technology Officer, is presenting  at CARTES SECURE CONNEXIONS AMERICA ... 5-7, 2015. The three-day conference is organized ... is speaking in is themed Global Fraud: Where is ...
(Date:4/27/2015)... 27, 2015 Profile Solutions, Inc. (OTC: PSIQ), ... systems is pleased to announce that Dr Gerry ... and member of its scientific advisory board. ... a thought leader in technology-enhanced learning models. He was ... has published studies and books focused on online student ...
(Date:4/20/2015)... , April 20, 2015 ...   Glenbeigh Records Management (GRM), Ireland,s ... with Dubai Islamic Bank. Having built up an impressive track ... now a leading player within the records management sector in ... expects to double is GCC staffbase and employ a further ...
Breaking Biology News(10 mins):NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3
... 12, 2012 The California Institute for Regenerative Medicine ... Vincent Chen, Ph.D., associate professor at Sanford-Burnham Medical Research ... projects funded as part of CIRM,s Basic Biology IV ... our understanding of stem cells and how to work ...
... for the synthesis of proteins, interspersed with noncoding regions ... in a new and unannotated genome is one of ... the Indian Institute of Technology in Delhi have used ... exons an order of magnitude faster than previously developed ...
... the body of a dead jay, according to new research ... can last for up to half an hour. Anecdotal ... birds in the crow family, react to dead of their ... carried out the work. But few experimental studies have explored ...
Cached Biology News:California's stem cell agency boosts heart disease research at Sanford-Burnham 2Scrub jays react to their dead 2
Request Info...
Mouse monoclonal [3G131] to Desmoglein 1 ( Abpromise for all tested applications). entrezGeneID: 1828 SwissProtID: Q02413...
TCP-1 alpha (H-110)...
Synphilin 1 Immunogen: Synthetic peptide corresponding to residues S(829) L E L N G E K D K D K G R T L Q R T(847) of human Synphilin 1. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products: